Another phase 2 trial was conducted on children with intermediate risk AML administering low intensity LD regimen followed by infusing highly purified KIR-HLA mismatched NK cells from haploidentical donors and SC IL-2 [38]. Here, IL2 is linked to acute myeloid leukemia.